Drug Trial Radar · NCT06494527
A Phase 1 Study to Evaluate the Safety/Tolerability, PK/PD of RG002C0106 Injection in Healthy Adults
Last checked: Nov 19, 2026Latest source record: Oct 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
50
Actual
Start
Oct 18, 2024
Primary completion
Aug 6, 2026
Study completion Aug 10, 2026
Sponsor
- Lead sponsor
- Rigerna Therapeutics Co., Ltd.; Rigerna Therapeutics (Beijing) Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jul 10, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 60 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability and PK/PD profiles of RG002C0106 injection in healthy adult subjects. The study will be divided into the following parts: Part A, conducted : SAD stage Part B, conducted: MAD stage
Conditions
- Safety Issues
Interventions
RG002C0106Drug
RG002C0106 is a siRNA drug targeting complement C3 to silence the related gene through the RNA interfering mechanism and inhibit the expression of C3 protein.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of adverse events (AEs) and serious adverse events (SAEs) related to the investigational drugTime frame: up to 169 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Beijing Friendship Hospital, Capital Medical University
Beijing, Beijing Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.